Abstracts tagged "Myositis"

Abstract Number: 1163 • ACR Convergence 2024
Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Aurélie Mourot¹, Beatrice Panuta¹, Juliette Charbonneau¹, Ange Mounkam Ngeuleu¹, Caroline Vo², Eric Rich³, Josiane Bourré-Tessier³, Edith Villeneuve³, Hélène Manganas³, Andréanne Gauthier³, Julie Morisset³, Sabrina Anh-Tu Hoa³ and Océane Landon-Cardinal³, ¹University of Montreal, Montreal, QC, Canada, ²Hôpital Charles Lemoyne, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada
Background/Purpose: Antisynthetase syndrome (ASSD) is characterized by interstitial lung disease (ILD), myositis, polyarthritis, Raynaud’s phenomenon, dermatomyositis-like rash and mechanic’s hands. ILD may present with isolated…
Abstract Number: 1734 • ACR Convergence 2024
Safety and Efficacy Data from a Phase I Trial of Umbilical Lining-Derived Stem Cells (ULSC) in Adult Dermatomyositis/Polymyositis
Michael R Bubb`¹, Eileen Handberg¹, Rafael Gonzalez², Blas Betancourt¹, J. Nicole Bostick¹, Sarah Long¹, Keith March¹ and Carl Pepine¹, ¹University of Florida, Gainesville, FL, ²Restem, LLC, Corona, CA
Background/Purpose: Mesenchymal stem/stromal cells are self-renewing, multi-potent stromal cells which act as modulators of immune responses. Umbilical cord-derived mesenchymal stromal cells, a classification of cells…
Abstract Number: 2076 • ACR Convergence 2024
Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience
ABHILASHA ARVIND MANWATKAR¹, Ajith Sivadasan², adinair Vijakrishnan², John Antony Jude Prakash³, chandhu aS⁴, JOHN KUMAR DAS⁵, Meera S N², illiasul Ibad k² and JOHN MATHEW¹, ¹christian medical college, vellore, Tamil Nadu, India, ²Christian Medical College, vellore, ³Chritian Medical College, Vellore, ⁴CMC Vellore, Vellore, Tamil Nadu, India, ⁵Christian Medical College, Vellore, India
Background/Purpose: There is a relative scarcity of studies on the effective management of Anti-signal recognition particle (anti-SRP) myositis. Recent consensus on anti-SRP myositis shows that…
Abstract Number: 2667 • ACR Convergence 2024
Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein
Jon Musai¹, Sahana Jayaraman², katherine Pak³, Iago Pinal-Fernandez⁴, Sandra Muñoz-braceras⁵, Maria Casal-Dominguez⁶, Eric Cho⁵, Fa'alataitaua Fitisemanu⁵, jose milisenda⁷, Lisa Rider⁸, Adam Schiffenbauer³, Albert Selva-O’Callaghan⁹, Thomas E Lloyd¹⁰, Lisa Christopher-Stine¹¹, Peter Burbelo¹², Benjamin Larman¹¹ and Andrew Mammen¹³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³National Institutes of Health, Bethesda, MD, ⁴NIAMS/National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁶NIAMS, NIH, Bethesda, MD, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIEHS, NIH, Garrett Park, MD, ⁹Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ¹⁰Johns Hopkins University School of Medicine, Lutherville, MD, ¹¹Johns Hopkins University, Baltimore, MD, ¹²National Institute of Dental and Craniofacial Research, Bethesda, MD, ¹³NIH, Bethesda, MD
Background/Purpose: Many myositis patients have myositis-specific autoantibodies (MSA) that define unique clinical phenotypes. For instance, dermatomyositis (DM) patients with anti-Mi2 autoantibodies have weaker muscles, higher…
Abstract Number: 0334 • ACR Convergence 2024
Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity
shiri keret¹, Tanya Chandra², Lisa Kaly³, Raisa Silva⁴, Eugenia Gkiaouraki⁵, Nantakarn Pongtarakulpanit⁶, shreya Sriram⁵, Rajesh Gopalarathinam⁷, Siamak Mogahadam⁶, Chester Oddis⁶ and Rohit Aggarwal⁸, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ⁴Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology, Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Creatine kinase (CK) is an important biomarker for the diagnosis and monitoring of Idiopathic Inflammatory Myopathies (IIM). However, in some cases, CK levels might…
Abstract Number: 1143 • ACR Convergence 2024
Epidemiology and Spectrum of Idiopathic Inflammatory Myopathies in Individuals of Sub-Saharan Ancestry: Data from the Tertiary Care Center of the Caribbean Island of Martinique
Benoit Suzon¹, Rachel Robert¹, Fabienne Louis-sidney², Arthur Felix¹, Illitch Coco-Viloin¹, Florence Moinet³, Rodolphe Cougnaud¹, Rémi Bellance¹, Emmanuelle Amazan¹, Emma pierrisnard¹, Moustapha Agossou¹, Christophe Deligny⁴ and Aurore Abel¹, ¹University Hospital of Martinique, Fort-de-France, Martinique, ²University Hospital Martinique, Fort De France, Martinique, ³University Hospital of Martinique, Fort de France, France, ⁴University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous systemic autoimmune diseases with a worldwide incidence ranging from 0.116 to 1.9 and a prevalence from 2.4 to…
Abstract Number: 1164 • ACR Convergence 2024
IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients
Asim Mohamed¹, Liron Caplan² and Melissa Griffith³, ¹PGY5, Aurora, CO, ²Rocky Mountain Regional VAMC, Aurora, CO, ³University of Colorado, Aurora, CO
Background/Purpose: Immune Mediated Necrotizing Myopathy (IMNM) is a debilitating but understudied entity. Correlations of demographic and clinical features with pathological findings remain underexplored. In addition,…
Abstract Number: 1735 • ACR Convergence 2024
High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial
Kristofer Andreasson¹, Cecilia Leijding¹, Maryam Dastmalchi², Antonella Notarnicola³, Stefano Gastaldello¹, Heléne Sandlund², Daniel Andersson⁴, Ingrid Lundberg⁵ and Helene Alexanderson², ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska University hospital, Stockholm, Sweden, ³Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Karolinska Institutet, Solna, Sweden, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Exercise is a recognized adjunctive therapy for patients with idiopathic inflammatory myopathies (IIM), enhancing physical capacity and reducing inflammation. Hitherto, moderate-to-intensive exercise has been…
Abstract Number: 2077 • ACR Convergence 2024
Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts
Travis Kinder and James Inglese, National Institutes of Health, Rockville, MD
Background/Purpose: The family of Janus kinases (JAK1, JAK2, JAK3, TYK2) mediate signal transduction from cytokine receptors through phosphorylation and activation of intracellular signaling pathways and…
Abstract Number: 2668 • ACR Convergence 2024
Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Silvia Cavalli¹, Fabricio Espinosa-Ortega², Ryan A. Adams³, Lauren Guy³, Charlotta Preger⁴, Càtia Fernandes-Cerqueira⁵, Roberto Caporali⁶, Ingrid Lundberg⁷ and Antonella Notarnicola⁸, ¹University of Milan, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁵4Dcell, Montrueil, Ile-de-France, France, ⁶Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
Abstract Number: 0288 • ACR Convergence 2023
Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM)
Sangmee Bae¹, Ani Shahbazian¹, Jennifer Wang², Dawoud Sulaiman³, David Meriwether⁴, srinivasa Reddy⁵ and Christina Charles-Schoeman⁶, ¹UCLA Rheumatology, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³UCLA Cardiology, Los Angeles, CA, ⁴UCLA Digestive Diseases, Los Angeles, CA, ⁵UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, ⁶UCLA Medical Center, Santa Monica, CA
Background/Purpose: Lipid oxidation products produced by artery wall cells under oxidative stress not only regulate immune responses, but their accumulation in HDL are shown to…
Abstract Number: 0748 • ACR Convergence 2023
Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT
Kastriot Kastrati¹, Thomas S Nakuz², Oana C Kulterer², Stephan Blüml³, Michael Bonelli³, Irina Gessl⁴, Hans-Peter Kiener³, Werner Langsteger², Daniel Mrak³, Florian Prayer⁵, Helmut Prosch⁵, Elisabeth Simader³, Tatjana Traub-Weidinger², Daniel Aletaha⁶, Helga Radner⁷, Marcus Hacker² and Peter Mandl³, ¹Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ⁷Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
Abstract Number: 1170 • ACR Convergence 2023
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
Abstract Number: 1945 • ACR Convergence 2023
Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals
Arturo Llobell¹, Inigo Gonzalez-Mazon², carmen secada³, Adrian Martin-Gutierrez³, Almudena García-Castaño³, Enrique Gallardo⁴, Soledad Retamozo⁵, Antonio Gomez-Centeno⁶, Luis Fernandez-Morales⁴, Jordi Gratacos Masmitja⁷ and Ricardo Blanco⁸, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Parc Taulí University Hospital, Sabadell, Spain, ⁵Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain, ⁶Parc Taulí Hospital Universitari, Sabadell, Spain, ⁷University Hospital Parc Taulí, Sabadell, Spain, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Myositis is a rare inflammatory complication associated with immune related adverse events (irAE) of immune checkpoints inhibition (ICI) immunotherapy1. It is characterized by musculoskeletal…
Abstract Number: 1967 • ACR Convergence 2023
Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment
Ana Valle¹, Talia Meisel¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Over the last few decades, it has been established that multiple infections can mimic idiopathic inflammatory myopathies (IIM). HIV, HTLV-1, and Lyme disease are…

« Previous Page
1
…
5
6
7
8
9
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].